Invertase | MON 810 5'-junction | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Investigated characteristic | TaqMan® | LNA® | CPT | Lux™ | Plexor™ | TaqMan® | LNA® | CPT | Lux™ | Plexor™ |
Detection limit (No. of copies) | 4 | 20 | 20 | 20 | 4 | 4 | 4 | 20 | 4 | 20 |
Quantification limit (No. of copies) | 100 | 100 | 400 | 200 | 100 | 100 | 20 | 100 | 100 | 100 |
Amplification efficiency (%) | 95 | 97 | 93 | 90 | 91 | 97 | 101 | 98 | 93 | 86 |
Dynamic range (No. of copies) | 100–40 000 | 100–40 000 | 400–40 000 | 200–40 000 | 100–40 000 | 100–4000 | 20–4000 | 100–4000 | 100–4000 | 100–8000 |
Repeatability in dynamic range, Cv (%) | 7.5 | 10.6 | 13.7 | 10.4 | 12.7 | 10.3 | 9.6 | 4.9 | 11.3 | 12.7 |
PCR inhibition at the highest copy number (No. of inhibited cases/all cases) | 0/2 | 0/2 | 0/2 | 0/2 | 0/2 | 1/2 | 2/2 | 2/2 | 2/2 | 0/2 |